Insider Transactions Reported by 25 Insiders of Evelo Biosciences, Inc.

Symbol: EVLO on OTC
Location: Foxboro, MA

Quick Takeaways

EVLO - Evelo Biosciences, Inc. has 25 insiders with reported activity on this page.
No net insider buy/sell flow is currently reported for the last year.
Recent transaction rows are not currently available.

What Changed

No meaningful buy/sell imbalance is currently visible in the one-year window.
Activity will update as new Forms 3/4/5 are filed.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Source Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 19 Apr 2025.

Buys

Shares: 0

Insiders: 0

Sells

Shares: 0

Insiders: 0

Net

Shares: 0

Insiders: 0

Window (months)	Buy $	Sell $	Net $
0-3	$0	$0	$0
3-6	$0	$0	$0
6-9	$0	$0	$0
9-12	$0	$0	$0

Evelo Biosciences, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Valuation	Report Date
Flagship Pioneering Fund VII General Partner LLC	10%+ Owner	$4,520,548	Mixed	27 May 2022
Flagship Ventures Fund IV General Partner LLC	10%+ Owner	$2,617,765	Mixed	11 Jul 2023
Horizon Technology Finance Corp	10%+ Owner	$714,286	Mixed	11 Jul 2023
David R. Epstein	Director	$30,998	Mixed	30 Jun 2022
Mark Bodmer	CSO, President of R&D	$8,492	Filing P/S	07 Nov 2023
Marella Thorell	Chief Financial Officer	$7,345	Filing P/S	07 Nov 2023
Simba Gill	President & CEO, Director	$5,860	Filing P/S	07 Nov 2023
Duncan McHale	Chief Medical Officer	$5,605	Filing P/S	07 Nov 2023
Mark D. Plinio	Chief Commercial Officer	$1,238	Mixed	31 Jan 2023
Stephen J. Carriere	Principal Accounting Officer	$67	Mixed	19 Jan 2023
Luca Scavo	Cfo		Mixed	19 Jan 2022
Lord Ara Darzi	Director		Mixed	09 Jun 2022
Iain B. McInnes	Director		Mixed	08 Jun 2023
Tonya Williams	Director		Mixed	08 Jun 2023
Alexander C. Reynolds	Director		Mixed	11 Jul 2023
Kyriazi Theo Melas	Director		Mixed	08 Jun 2023
Daniel Char	General Counsel		Mixed	19 Jul 2022
John Hohneker	Director		Mixed	08 Jun 2023
Julie McHugh	Director		Mixed	08 Jun 2023
Jeffrey R. Moore	Director		Mixed	11 Jul 2023
Robert L. Rosiello	Director		Mixed	08 Jun 2023
David P. Perry	Director		Mixed	08 Jun 2021
Jose-Carlos Gutierrez-Ramos	Director		Mixed	08 Jun 2023
Juan Andres	Director		Mixed	08 Jun 2023
Jonathan B. Zung	Chief Development Officer		Mixed	19 Jul 2022

Top shareholders of Evelo Biosciences, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Flagship Pioneering Fund VII General Partner LLC	3/4/5	10%+ Owner	— class O/S missing	13,698,630	$4,520,548	—	27 May 2022	3/4/5
Flagship Ventures Fund IV General Partner LLC	3/4/5	10%+ Owner	— class O/S missing	7,932,624	$2,617,765	—	11 Jul 2023	3/4/5
Horizon Technology Finance Corp	3/4/5	10%+ Owner	— class O/S missing	2,164,502	$714,286	—	11 Jul 2023	3/4/5
David R. Epstein	3/4/5	Director	— class O/S missing	93,932	$30,998	—	30 Jun 2022	3/4/5
Mark Bodmer	3/4/5	CSO, President of R&D	— mixed-class rows	32,357 mixed-class rows	$8,492	—	07 Nov 2023	3/4/5
Marella Thorell	3/4/5	Chief Financial Officer	— mixed-class rows	28,759 mixed-class rows	$7,345	—	07 Nov 2023	3/4/5
Simba Gill	3/4/5	President & CEO, Director	— mixed-class rows	32,994 mixed-class rows	$5,860	—	07 Nov 2023	3/4/5
Duncan McHale	3/4/5	Chief Medical Officer	— mixed-class rows	23,484 mixed-class rows	$5,605	—	07 Nov 2023	3/4/5
Mark D. Plinio	3/4/5	Chief Commercial Officer	— class O/S missing	3,750	$1,238	—	31 Jan 2023	3/4/5
Stephen J. Carriere	3/4/5	Principal Accounting Officer	— mixed-class rows	1,266 mixed-class rows	$67	—	19 Jan 2023	3/4/5
Jonathan B. Zung	3/4/5	Chief Development Officer	— class O/S missing	115,000	—	—	19 Jul 2022	3/4/5
Luca Scavo	3/4/5	CFO	— class O/S missing	60,000	—	—	19 Jan 2022	3/4/5
Daniel Char	3/4/5	General Counsel	— class O/S missing	40,000	—	—	19 Jul 2022	3/4/5
Lord Ara Darzi	3/4/5	Director	— class O/S missing	30,000	—	—	09 Jun 2022	3/4/5
Robert L. Rosiello	3/4/5	Director	— class O/S missing	30,000	—	—	08 Jun 2023	3/4/5
Iain B. McInnes	3/4/5	Director	— class O/S missing	20,000	—	—	08 Jun 2023	3/4/5
John Hohneker	3/4/5	Director	— class O/S missing	20,000	—	—	08 Jun 2023	3/4/5
Jose-Carlos Gutierrez-Ramos	3/4/5	Director	— class O/S missing	20,000	—	—	08 Jun 2023	3/4/5
Juan Andres	3/4/5	Director	— class O/S missing	20,000	—	—	08 Jun 2023	3/4/5
Julie McHugh	3/4/5	Director	— class O/S missing	20,000	—	—	08 Jun 2023	3/4/5
Kyriazi Theo Melas	3/4/5	Director	— class O/S missing	20,000	—	—	08 Jun 2023	3/4/5
Tonya Williams	3/4/5	Director	— class O/S missing	20,000	—	—	08 Jun 2023	3/4/5
Alexander C. Reynolds	3/4/5	Director	— class O/S missing	2,000	—	—	11 Jul 2023	3/4/5
Jeffrey R. Moore	3/4/5	Director	— class O/S missing	2,000	—	—	11 Jul 2023	3/4/5
David P. Perry	3/4/5	Director	— class O/S missing	1,810	—	—	08 Jun 2021	3/4/5

Recent Insider Transactions by Companies or Individuals for Evelo Biosciences, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
No insider transactions were found in the last 12 months for this issuer.

* An asterisk sign (*) next to the price indicates that the price is likely invalid.